Efficacy and Safety on Prouk for STEMI Patients in China
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.
Also called NCT02367976
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 450 participants
- Sponsor
- Suzhou RxD Biopharmaceutical Co., Ltd
- Registry
-
NCT02367976
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02367976. Randomized; single masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety on Prouk for STEMI Patients in China
- Condition
- STEMI
- Intervention (Drug)
- rhprouk
- Lead sponsor
- Suzhou RxD Biopharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct02367976- Content hash
223e106cd06c35c65bef912222a9bfeca79da1da228bcd47a4016a63ac0294e6